Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

Abstract Background Cardiac glycosides are approved for the treatment of heart failure as Na+/K+ pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identification of a specific cancer type defined by a molecular signature to des...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Elodie M. Da Costa, Gregory Armaos, Gabrielle McInnes, Annie Beaudry, Gaël Moquin-Beaudry, Virginie Bertrand-Lehouillier, Maxime Caron, Chantal Richer, Pascal St-Onge, Jeffrey R. Johnson, Nevan Krogan, Yuka Sai, Michael Downey, Moutih Rafei, Meaghan Boileau, Kolja Eppert, Ema Flores-Díaz, André Haman, Trang Hoang, Daniel Sinnett, Christian Beauséjour, Serge McGraw, Noël J.-M. Raynal
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-06-01
coleção:	Journal of Experimental & Clinical Cancer Research
Assuntos:	Cardiac glycosides Proscillaridin A MYC Leukemia Lysine acetylation Chromatin remodelling
Acesso em linha:	http://link.springer.com/article/10.1186/s13046-019-1242-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!